040. Brorphine, Isotonitazene and Metonitazene Emerge as New Age Opioids

Alexandra M Amaducci, Kim Aldy, Sharan Campleman, Alison Meyn, Stephanie Abston, Alex Krotulski, Barry Logan, Paul Wax, Jeffrey Brent, Alex F Manini, On Behalf of the Toxicology Investigators Consortium (ToxIC) Fentalog Study Group

1 Lehigh Valley Health Network-USF Morsani College of Medicine, Allentown, PA, USA. 2 American College of Medical Toxicology, Phoenix, AZ, USA. 3 University of Texas Southwestern Medical Center, Dallas, TX, USA. 4 Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, PA, USA. 5 NMS Labs, Horsham, PA, USA. 6 University of Colorado School of Medicine, Aurora, CO, USA. 7 Icahn School of Medicine at Mount Sinai, New York, NY, USA

Background: New Age Opioids (NAOs) are classified as new nonfentanyl opioids in the illicit opioid supply. Brorphine, isotonitazene and metonitazene are NAOs with a piperidine benzimidazolone structure.

Research Question: We report six cases of opioid overdose found to contain NAOs.

Methods: This case series is from the Toxicology Investigators Consortium (ToxIC) Fentalog Study Group, an ongoing multicenter study across the United States. Consecutive ED patients with a presumed acute opioid overdose and residual blood samples were included. Exclusion criteria were: age < 18, prisoners, and those with nontoxicologic diagnoses. Information collected by chart review included demographics, past medical and substance use history, clinical course, vital signs, and disposition. Discarded blood samples for all included patients were sent for toxicologic confirmation performed by liquid chromatography quadrupole time-of-flight mass spectrometry for the presence of over 900 substances including novel psychoactive substances and their metabolites.

Results: Between 10/6/20-10/31/21, 412 cases met inclusion criteria, with six positive for brorphine, isotonitazene and metonitazene. Age range was 20-57. The majority were female (n = 4). All patients presented with an opioid toxidrome and received naloxone. All samples contained fentanyl and a stimulant. In the two brorphine cases, they reported using a parental opioid such as heroin or fentanyl. Both had a depressed level of consciousness (DLOC) and respiratory depression which were reversed with up to two naloxone doses. Isotonitazene was detected in two patients; both had DLOC and received two naloxone doses. The two patients that were found to have metonitazene presented in cardiac arrest. One patient died despite six mg of naloxone and the other survived after receiving 10 mg of naloxone.

Conclusion: NAOs may confound a typical opioid overdose presentation and might require higher than typical naloxone dosing. Both metonitazene patients had cardiac arrests, and other NAOs had decreased response to naloxone likely due to high potency.